CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger

PartnershipPositive
AI Analysis

Summary

Eli Lilly entered into a collaboration and licensing agreement with OmniAb for ion channel drug discovery, with potential payments up to $370 million. Separately, Slate and Fulcrum announced a reverse merger.

Importance:7/10
Sentiment:
0.60
partnershiplicensingcollaborationion channelGLP-1merger
Related Companies

Read the original article

Published by Endpoints News on August 17, 2026 2:36 PM

Read Original